Biohaven Therapeutics Ltd.

This early-stage study tests whether BHV-1400 is safe and tolerable for people with IgA nephropathy, a kidney disease. About 20 adults with confirmed IgA nephropathy will receive the drug and be monitored for side effects. The goal is to see if the drug is safe enough to study fu…

This study tests whether a new drug called BHV-8000 can slow the worsening of symptoms in people recently diagnosed with Parkinson's disease. About 550 adults aged 40-85 with early Parkinson's will receive either the drug or a placebo. The main goal is to see if the drug delays p…

This early-stage study tests a new drug called BHV-1530 in about 95 adults with advanced or metastatic solid tumors that have not responded to other treatments. The main goals are to find a safe dose and check for side effects. Researchers will also watch for signs that the drug …

This study tests a new drug, BHV-1510, in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first, finding the safest dose, and second, checking if the drug shrinks tumors when used alone or with another cancer drug (cemip…

This early-stage study tests whether BHV-1300 is safe for people with Graves' disease, an autoimmune condition that causes an overactive thyroid. About 15 adults will receive the drug and be monitored for side effects and changes in disease markers. The goal is to see if the drug…

This study tests a new medication, BHV-7000, for people with focal epilepsy that hasn't improved with other treatments. About 390 adults aged 18-75 will receive either the drug or a placebo to see if it safely reduces seizure frequency. The goal is to better control seizures, not…

This study tests whether the drug BHV-7000 can safely reduce seizure frequency in adults with focal epilepsy that hasn't improved with other treatments. About 390 participants will receive either one of two doses of BHV-7000 or a placebo, and researchers will compare seizure coun…